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A pivotal role has emerged for glycogen synthase kinase-3 (GSK3) as an important contributor to Alzheimer’s disease pathology.
Evidence for the involvement of GSK3 in Alzheimer’s disease pathology and neuronal loss comes from studies of GSK3
overexpression,GSK3localizationstudies,multiplerelationshipsbetween GSK3andamyloidβ-peptide (Aβ),interactionsbetween
GSK3 and the microtubule-associated tau protein, and GSK3-mediated apoptotic cell death. Apoptotic signaling proceeds by
either an intrinsic pathway or an extrinsic pathway. GSK3 is well established to promote intrinsic apoptotic signaling induced
by many insults, several of which may contribute to neuronal loss in Alzheimer’s disease. Particularly important is evidence
that GSK3 promotes intrinsic apoptotic signaling induced by Aβ. GSK3 appears to promote intrinsic apoptotic signaling by
modulating proteins in the apoptosis signaling pathway and by modulating transcription factors that regulate the expression of
proteins involved in apoptosis. Thus, GSK3 appears to contribute to several neuropathologicalmechanismsin Alzheimer’s disease,
including apoptosis-mediated neuronal loss.
1.Introduction
Ten years ago we ﬁrst noted that glycogen synthase kinase-3
(GSK3)appeared tobe linkedtoall ofthemajor pathological
mechanisms that had been identiﬁed in Alzheimer’s disease
[1]. Since then, a remarkable amount of new evidence has
solidiﬁedthecentralroleofGSK3inAlzheimer’sdiseaseneu-
ropathology,as exempliﬁedby thisentire issue beingdevoted
to the subject. Among the early identiﬁed links between
GSK3 and Alzheimer’s disease was the discovery that GSK3
promotes the intrinsic apoptotic signaling pathway that may
be partly responsible for neuronal loss in Alzheimer’s disease
[2].Herewereviewthemultiplecellularpathwaysinﬂuenced




Among the known mechanisms that may contribute to
loss of neurons in Alzheimer’s disease brain, apoptosis has
received the most attention. Apoptotic signaling is generally
classiﬁed as proceeding by either an intrinsic pathway or an
extrinsic pathway. Of these, the intrinsic apoptotic signaling
pathway has predominated in studies of Alzheimer’s disease.
Intrinsic apoptotic signaling is most often induced by
intracellular damage that leads to mitochondrial release of
cytochrome c and the activation of intracellular cysteine
proteases called caspases [3], particularly caspase-9 and
caspase-3, with a variety of other pro-apoptotic media-
tors and caspases contributing to the eventual outcome2 International Journal of Alzheimer’s Disease
of apoptosis [4]. Extrinsic apoptotic signaling is initiated
by stimulation of plasma membrane death receptors that
initiate apoptosis by activation of caspase-8, and subsequent
apoptotic signaling can proceed through the mitochondrial
pathway or independently of mitochondria by caspase-8-
mediated direct activation of caspase-3 [5]. Of these two
apoptotic signaling pathways, the intrinsic system has been
the focus of the great majority of studies of apoptotic cell
death mechanisms in Alzheimer’s disease.
3.GSK3PromotesIntrinsicApoptoticSignaling
Much evidence indicates that promotion of the intrinsic
apoptotic signaling pathway by GSK3 may be particularly
important in the apoptosis and neuronal loss that occurs in
Alzheimer’s disease. This is because GSK3 has been shown
to promote apoptosis following a wide range of insults
that activate the intrinsic apoptotic signaling pathway [2].
In order to promote intrinsic apoptotic signaling, GSK3
must be active. The major mechanism regulating GSK3
activity is phosphorylation of an N-terminal serine in
each of the two paralogs (commonly called isoforms) of
GSK3, serine9-GSK3β or serine21-GSK3α. Phosphorylation
of these regulatory serines inhibits GSK3, thus signaling
activities that reduce GSK3 serine-phosphorylation activate
GSK3.TheinhibitoryserinesinGSK3canbephosphorylated
by several diﬀerent kinases. The most often studied of these
is Akt (also called protein kinase B), which itself is activated
by multiple receptor-coupled signaling pathways that signal
through phosphatidylinositol 3-kinase (PI3K), such as sig-
naling induced by a variety of neurotrophin receptors. Thus,
one mechanism by which GSK3 can be activated is by signals
that reduce its serine-phosphorylation mediated by Akt or
other kinases. A widely used method to study the actions
of GSK3β is to express GSK3β with a serine9-to-alanine9
mutation (S9A-GSK3β) to maintain expressed GSK3β fully
active. GSK3 also must be phosphorylated on a tyrosine
residue for full activity, tyrosine216-GSK3β or tyrosine279-
GSK3α. Although the mechanisms regulating tyrosine-
phosphorylation of GSK3 are still not well-understood, a
number of reports have indicated that GSK3 activity can be
increased by signals that increase tyrosine-phosphorylated
GSK3.
3.1. Overexpression of GSK3 Is Suﬃcient to Activate Apoptosis.
Overexpression of GSK3 in cells or rodent brains has been
shown to induce apoptosis and neuronal death in many
reports. Theﬁrst studyofthistypeshowed thatthattransient
overexpression of wild-type GSK3β was suﬃcient to induce
apoptosisinculturedPC12cells[6].Furthermore,thisreport
showed that expression of a dominant-negative kinase-dead
mutant of GSK3β was suﬃcient to reduce apoptosis that
was induced by inhibition of PI3K, demonstrating that
GSK3 is a major mediator of apoptosis in conditions of
reduced PI3K activity [6]. Bijur and colleagues [7]e x t e n d e d
those ﬁndings to show that although relatively low levels of
over-expressed GSK3β did not induce apoptosis in human
neuroblastoma SH-SY5Y cells, pro-apoptotic signaling was
greatly increased by modestly elevated levels of GSK3β,
demonstrating that increased GSK3 activity promotes apop-
totic signaling induced by a variety of toxic agents [7]. These
andotherin vitro studiesdemonstratingthatincreased GSK3
activity can promote activation of the intrinsic apoptotic
signaling pathway and that inhibition of GSK3 provides
protection from apoptosis have been previously reviewed in
detail [1, 2].
The results of in vitro studies that showed promotion of
intrinsic apoptotic signaling by GSK3 raised the question of
whether abnormal increases in GSK3 in vivo may contribute
to neuronal death in neurodegenerative diseases, such as
Alzheimer’s disease. One approach to test this that has
been productive is to study transgenic mice over-expressing
GSK3. Spittaels and colleagues [8] studied transgenic mice
over-expressing constitutively active S9A-GSK3β and found
hyperphosphorylation ofthemicrotubule-associated protein
tau and altered behaviors in sensorimotor tasks in these
mice. Mice postnataly over-expressing S9A-GSK3β driven by
the thy-1 promoter in neurons exhibited decreased brain
volume and cell size, increased neuronal densities, and
learning deﬁcits in the Morris water maze [9]. Lucasand col-
leagues [10] created transgenic mice over-expressing GSK3β
in regions speciﬁcally relevant to Alzheimer’s disease, the
hippocampus and neuronal layers I–VI of the cortex. These
mice displayed evidence of apoptosis activation, including
increased TUNEL staining and caspase-3 activation in the
dentate gyrus [10]. Concomitant with increased markers
of apoptosis, the GSK3β-over-expressing mice exhibited
activated astrocytes and microglia. These mice also displayed
deﬁcits in learning in the Morris water maze, but tau
ﬁlaments were concluded to not be involved in the learning
deﬁcits [11]. Further studies of these mice took advan-
tage of the capability of terminating GSK3β overexpression
with doxycyclin treatment, which reduced GSK3β levels,
reduced tau phosphorylation, increased microtubule poly-
merization, reduced reactive astrocytosis, restored spatial
memory, and decreased levels of active caspase-3 [12]. When
the tetracycline-regulated conditional transgenic mice were
crossed with mice over-expressing tau carrying a FTDP-17
mutation, GSK3-mediated hyperphosphorylated tau had an
increased propensity to form ﬁlaments, leading to neuroﬁb-
rillary tangles (NFTs), and displayed microencephaly at 18
months of age [13]. Expression of constitutively active S9A-
GSKβ in the cortex and hippocampus caused hyperphos-
phorylated tau, neuroﬁbrillary tangles, and morphological
changes in neuronal structure [14]. Mice expressing human
P301L tau (JNLP3 mice), expressing mutant amyloid pre-
cursor protein (Tg2576 mice), and expressing both P301L
t a um u t a t i o na n dm u t a n tA P Pp r o t e i n( T A P Pm i c e ) ,a l l
displayed increased tyrosine-phosphorylated GSK3α/β in
spinal cord and amygdala neurons characterized by gran-
ulovacular degenerative granules and neuroﬁbrillary tangles
in the JNPL3 and TAPP mice [15]. Avila and colleagues
[16] reported that mice over-expressing GSK3β had a 2-fold
increase in tau levelsand a decrease in dentate gyrus volume,
and suggested that increased GSK3β activity, particularly in
the dentate gyrus, hinders neurogenesis, thereby promoting
the decreased tissue volume. Collectively, these ﬁndings inInternational Journal of Alzheimer’s Disease 3
transgenic mice indicate that GSK3 promotes pathological
process associated with Alzheimer’s disease, but whether
GSK3 promoted decreases in neuronal viability often was
not directly investigated due to the diﬃculty in capturing
transient markers of apoptosis in in vivo studies.
3.2. Localization of GSK3 in Alzheimer’s Disease Brain.
LocalizationstudiesinpostmortemAlzheimer’sdiseasebrain
have been used to determine if GSK3 is accumulated or
activated in areas with prominent neurodegeneration. Pei
and colleagues [17] reported increased GSK3α and GSK3β
immunoreactivities in plaques and CA1 hippocampal neu-
rons, and co-staining with Congo red indicated that many
cells with increased GSK3β immunoreactivity contained
hyperphosphorylated tau and neuroﬁbrillary tangles. Sub-
sequently, Pei and colleagues [18] compared non-diseased
brains, deemed Stage 0 cases, to Alzheimer’s disease-like
brains from middle-aged and senescent patients, classiﬁed as
stages A–C according to the extent of amyloid deposition,
and NF I–VI according to the extent of neuroﬁbrillary
tangle pathology. They found only moderate active GSK3β
staining in normal brains (Stage 0) in neurons of the
entorhinal cortex and CA1 and CA2 regions of the hip-
pocampus [18]. Inactive GSK3β staining was pronounced
in entorhinal cortical neurons and the hippocampal CA1
region relative to staining for active GSK3. Stage 0/NF I-II
brains also had increased inactive GSK3β, relative to active
GSK3, immunoreactivity in the entorhinal cortex and hip-
pocampal CA1 region. Stage III/IV brains showed increased
tau phosphorylation immunoreactivity (AT8 antibody) and
tangle formation in the entorhinal cortex and hippocam-
pal CA1 region, and tangle-containing neurons also had
increased active, as well as inactive, GSK3 immunoreactivity,
suggesting increases in both GSK3 levels and activity as
disease pathology progressed. Stage V/VI brains exhibited
AT8 immunoreactivity and tangle inclusions throughout
the entorhinal and temporal cortices and the hippocampus.
Most inclusion-positive neurons stained intensely for active
GSK3,while littleornoinactive GSK3immunoreactivity was
recorded in cortical or hippocampal tissues. Collectively, Pei
and colleagues [18] clearly deﬁned an Alzheimer’s disease
progression proﬁle detailing increased tau phosphorylation
and increased GSK3β expression and activity in cortical
and hippocampal tissues as disease pathology worsened.
Ferrer and colleagues [19] also found increased GSK3
immunoreactivity in degenerating neurons characterized by
tangle-like inclusions in Stage III and Stage VI postmortem
Alzheimer’s disease entorhinal cortex and hippocampus.
Furthermore, GSK3 colocalized with 40–80% of neurons
with hyperphosphorylated tau (PHF-1 antibody), thereby
supporting the notion that GSK3 expression and/or activity
increases as Alzheimer’s disease progresses.
GSK3 immunoreactivity has been reported to be in-
creased at sites of granulovacular degeneration, a patho-
logical characteristic of Alzheimer’s disease [15, 19, 20].
Leroy and colleagues [20] reported increased GSK3β and
phospho-tyr216-GSK3β immunoreactivity in neuronal cell
bodies and dendrites of postmortem human hippocampal
tissues. Increases in GSK3 immunoreactivity co-localized
speciﬁcally with granulovacular degenerative granules, and
there were no detectable changes in GSK3 immunoreactivity
within neuroﬁbrillary tangles.Ferrerandcolleagues[19]also
reported increased GSK3 immunoreactivity in granulovacu-
lar degenerative bodies located in neuronal cell bodies, and
also found increased GSK3 immunoreactivity in glial cells in
postmortem human brain tissues.
3.3. Toxicity Associated with Amyloid-β Peptide (Aβ). Sub-
stantial evidence has demonstrated that Aβ activates GSK3
by decreasing its inhibitory serine-phosphorylation, which
appears to contribute to Aβ-induced increased tau phos-
phorylation and toAβ-induced neurotoxicity[21–30].These
studies showing Aβ-induced activation of GSK3 have used
a variety of peptides, including Aβ1–40,A β1–42,a n dt h e
25–35 peptide fragment, indicating that accumulation of
any of these may activate GSK3, although perhaps by
utilizing diﬀerent signaling mechanisms, which remain to
be identiﬁed. Takashima and colleagues [21–24, 31]ﬁ r s t
identiﬁeda neuroprotectiveeﬀectof inhibiting GSK3(atthat
time also called tau protein kinase-1) against Aβ-induced
toxicity. They found that in cultured rat hippocampal
neurons Aβ treatment increased GSK3β activity and pre-
treatment with GSK3β antisense oligonucleotides prevented
Aβ-induced cell death and reduced tau phosphorylation.
These studies indicated that GSK3 is involved in Aβ-induced
tau phosphorylation and neurotoxicity. Subsequent reports
also demonstrated that inhibitors of GSK3, such as lithium
or SB216763, reduced Aβ-induced tau phosphorylation and
cell death in cultured neurons [27, 29, 32]. Inestrosa and
colleagues [33] found that treatment with lithium pre-
vented Aβ1−42-induced morphological changes, speciﬁcally
shrunken soma and aﬀected dendritic and axonal processes,
andreducedAβ-induceddecreasesincellviabilityofprimary
rat hippocampal neuronal cultures [33]. After injection of
Aβ into rathippocampus, increased GSK3immunoreactivity
was found near Aβ deposits [33]. Treatment with SB216763
or GSK inhibitor VIII also prevented Aβ-induced caspase-3
activation in vivo, decreased TUNEL positive neurons, pre-
vented tau-phosphorylation, reduced microglia activation,
decreased cytochrome c release from the mitochondria to
the cytosol, and improved deﬁcits in the Morris water maze
[27, 28]. GSK3 inhibitor VIII or lithium reduced Aβ1–42-
induced reduction in cell viability and reduced markers
of apoptosis [28]. Lithium treatment decreased cortical
tau phosphorylation and aggregates, and reduced axonal
degeneration [34]. Administration of the GSK3 inhibitor
NP12 decreased tau phosphorylation, decreased Aβ deposi-
tion, and improved performance in the Morris water maze
in amyloid precursor protein (APP) transgenic mice, and
reduced neuronal loss in the CA1region ofthe hippocampus
and the entorhinal cortex [35]. Rockenstein and colleagues
[36] also reported neuroprotectiveeﬀectsof inhibiting GSK3
with lithium using APP transgenic mice, with improvements
in the Morris water maze task, decreased Aβ immunore-
activity, decreased phospho-tau immunoreactivity, and an
increase in MAP2 staining (indicative of increased neuron4 International Journal of Alzheimer’s Disease
density) after treatment with lithium. The role of GSK3 was
further examined by crossing mice conditionally expressing
a dominant-negative (DN) GSK3β construct with hAPP
transgenic mice. These hAPP x DN-GSK3β mice displayed
improved performance in the Morris water maze, increased
MAP2 immunoreactivity, decreased Aβ immunoreactivity,
decreased phospho-tau immunoreactivity, and normal cell
morphologies, when compared to hAPP transgenic litter-
mates,suggestingthatinhibitionofGSK3canphenotypically
rescue hAPP mice [36]. Ma and colleagues [37] showed that
antibodies directed against Aβ increased inhibitory serine-
phosphorylation of GSK3, which was associated with a
decrease in neurotoxicity. Altogether, these and additional
reports have ﬁrmly established that Aβ activates GSK3 and
that reducing GSK3 activity provides protection from Aβ-
induced neurotoxicity.
Studies of the mechanism by which Aβ activates
GSK3 have indicated the involvement of the PI3K-Akt
pathway, which normally maintains inhibitory serine-
phosphorylation of GSK3. Aβ treatment was shown to cause
time-dependent decreases in PI3K activity and increases
in GSK3 activity [22]. Treatment of cultured cells with
Aβ1–42 reduced Akt phosphorylation, indicative of decreased
Akt activity [38, 39], activated GSK3β [38], and activated
caspase-3 [25], suggesting that decreased Akt activity con-
tributes to Aβ-induced activation of GSK3, which promotes
apoptosis.
In addition to acting downstream of Aβ in its neurotoxic
signaling, GSK3 likely also inﬂuences the neurotoxicity of
Aβ by regulating APP processing and the production of Aβ.
Takashima and colleagues [24]f o u n dt h a tG S K 3 β associated
with presenilin-1 in postmortem Alzheimer’s disease cortical
tissues and in COS-7 cells transiently transfected with wild-
type presenilin-1, which raised the possibility that GSK3
may regulate Aβ production. This was found in studies that
showed reducing GSK3 activity in vitro orin vivo diminished
the production of Aβ [40–42]. The mechanism by which
GSK3 promotes Aβ production remains to be determined,
but may be related to its phosphorylation and regulation of
presenilin-1 [24, 43]o ro fA P P[ 44].
β-Catenin destabilization has been suggested to be a
contributing factor in Aβ-induced GSK3-mediated neuro-
toxicity. GSK3 promotes the degradation of β-catenin, and
nuclear β-catenin levels were decreased in response to acute
Aβ treatments, indicating that Aβ-induced activation of
GSK3 led to increased degradation of β-catenin [45, 46].
Lucas and colleagues [10] reported decreased nuclear β-
catenin levels in GSK3 over-expressing mice. Presenilin-
1 (PS1), a GSK3 substrate, can regulate the turnover of
β-catenin [47, 48]. Kang and colleagues [48]f o u n dt h a t
GSK3co-immunoprecipitatedwith PS1 butnot with mutant
M146L or ΔX9 PS1. Overexpression of PS1 also increased
the GSK3β-β-catenin association, thereby facilitating GSK3-
mediated phosphorylation and subsequent degradation of
β-catenin. PS1 mutants were later linked to increased
GSK3 activity via decreased PI3K/Akt signaling, thereby
promoting decreased inhibitory serine-phosphorylation of
GSK3 in primary neuronal cultures [49]. In cultured
PS1−/− neurons the activated GSK3 was associated with
increased caspase-3 activation [49]. In HEK293 and SK-
N-MC cells, Kwok and colleagues [50] transiently over-
expressed GSK3βΔexon9+11,which lacksexons9and11and
is characterized by an increased propensity to phosphorylate
tau, and found decreased β-catenin levels and signaling.
Transient transfection of tau decreased β-catenin levels
by 25%, and co-expression of tau and GSK3βΔexon9+11
reversed the GSK3-mediated decrease in β-catenin signal-
ing. Inestrosa and colleagues have reported in detail that
activation of Wnt signaling, which inhibits GSK3-mediated
phosphorylation and degradation of β-catenin, is neuro-
protective against Aβ toxicity [33, 51–53]. Thus, reduced
levels of Wnt signalling-associated β-catenin may contribute
to GSK3-mediated neurotoxicity induced by Aβ produc-
tion and promoted by mutations in PS1 in Alzheimer’s
disease.
3.4. Toxicity Associated with Tau. The microtubule-associat-
edproteintauisoneofthemostwell characterized substrates
of GSK3[54]. Phosphorylation of tau by GSK3 promotestau
dissociation from microtubules, increasing destabilization of
microtubules [55]. Conversely, inhibition of GSK3 promotes
tau binding to microtubules and assembly of microtubules
[56]. As noted above, several studies have reported that
the GSK3-mediated increase in tau phosphorylation in
Alzheimer’s disease may result in part from Aβ-induced
activation of GSK3. GSK3-mediated tau phosphorylation
in Alzheimer’s disease has been suggested to promote tau
oligomerization,which canbetoxic[57,58],andaggregation
of tau and eventual neurodegeneration [54, 59]. Sahara
and colleagues [60] reported that overexpression of tau in
SH-SY5Y cells resulted in increased tau phosphorylation
and increased caspase-3 activity, suggesting a role in pro-
apoptotic signaling and cell death. It is possible that GSK3β-
mediated hyperphosphorylation of tau may promote tau-
mediated, as well as Aβ-mediated, neurotoxicity.
Transgenic mice have also been used to study the inter-
actions between tau and GSK3. Using protein preparations
from the brains and spinal cords of double transgenic mice
over-expressing GSK3β and human tau40-1, an isoform of
tau containing an additional 29 and 58 amino acid sequence
that promotes Alzheimer’s disease-like pathologies [61],
Spittaels and colleagues [8] found decreased tau binding
to microtubules in double transgenic mice, as compared
to transgenic mice littermates expressing human tau40-1
alone. The relationship between GSK3 and tau was found
to be more than a mere protein-protein interaction, as
Kwok and colleagues [50] found interactions between the
GSK3β and tau (MAPT) genes associated with increased
risk and incidence of Alzheimer’s disease. Using senescence-
accelerated mice (SAM), Tajes and colleagues [62]s h o w e d
that inhibition of GSK3 with lithium decreased calpain
activation and decreased caspase-3 activity. Primary neu-
ronal cultures treated with the GSK3 inhibitors lithium or
SB415286 exhibited decreased neurite disintegration, neu-
ronal shrinkage, and nuclear condensation, further impli-
cating GSK3 in neurodegenerative disease progression [62].
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treatment reduced tau aggregation [63]. Evidence of tau-
relatedtoxicityhasbeenbolsteredbystudiesoftau-knockout
mice [64]. Mice conditionally over-expressing GSK3 and
lacking tau performed better in the Morris water maze
task, as compared to GSK3 over-expressing littermates [64].
Knockout of tau reduced GSK3-mediated shrinkage of the
dentate gyrus and reduced reactive microglia, as GSK3-only
over-expressing littermates were characterized by increased
brain shrinkage and increased reactive microglia compared
to control and tau-knockout mice.
In addition to hyperphosphorylation of tau, GSK3 has
also been linked to alternate splicing of tau, thereby possibly
promoting pro-apoptotic oligomerization and tau-induced
cell death [65] .I n c l u s i o no fe x o n1 0l i k e l yp r o m o t e s
increased binding of tau and stabilization of microtubules,
thereby combating tau aggregate-mediated neuroﬁbril-
lary tangle formation and neurodegeneration observed in
Alzheimer’s disease. Hern´ andez and colleagues [65]e x a m -
ined the relationship between GSK3 and alternative splicing
of tau and found that in primary mouse cortical neurons
treatment with GSK3 inhibitors lithium or AR-A014418
decreased alternative splicing of tau and promoted the
increased presence of exon 10 in tau, which promotes micro-
tubule bundling and stabilization, as compared to exon 10-
absent tau [65, 66]. Alternative splicing of tau has also been
linked to caspase-mediated cleavage and aggregation of tau
in Alzheimer’s disease [67]. Alternative forms of tau have
been linked to increased tau aggregation in other cells and
cell systems [68].
Incontrasttoreportsoftauoligomerizationcontributing
to neurotoxicity, a few reports suggest a neuroprotec-
tive role for tau. Mouse neuroblastoma cells stably over-
expressing tauwere lessaﬀectedby apoptoticstimuli,includ-
ing staurosporine, camptothecin, and H2O2 treatments, and
over-expressed tau blocked GSK3 overexpression-mediated
increases in cell death, actions that may have resulted
from tau binding to GSK3 to block its induction of β-
catenin degradation, allowing up-regulated levels of β-
catenin, which supports cell survival [69]. Recently, Wang
and colleagues[70] found that overexpression of human tau,
in vivo in transgenic mice and in vitro in N2a cells, decreased
p53 levels, decreased mitochondrial cytochrome c release,
and decreased caspase-9 and caspase-3 activation. Treatment
with lithium exaggerated the decrease in p53 expression and
increased pro-apoptotic processes [70]. Thus, the connec-
tions between tau and GSK3 in aﬀecting neurodegeneration
remain to be further clariﬁed and may be complicated by
employing overexpression approaches.
3.5. GSK3 Promotes Insults Associated with Alzheimer’s Dis-
ease. As previously reviewed [2], GSK3 promotes apoptosis
induced by many insults that activate the intrinsic apop-
totic signaling pathway, some of which may contribute to
neuronal loss in Alzheimer’s disease. For example, oxidative
stress is increased in Alzheimer’s disease, as indicated by
increased markers of oxidative stress found in postmortem
Alzheimer’s disease brain [71–73], and has been associated
with the loss of neuronal viability, and GSK3 promotes
oxidative stress-induced cell death [2]. For example, Sch¨ afer
and colleagues [74] found that resistance to oxidative stress
was associated with decreased GSK3 activity. Aβ treatment
of cells increases oxidative stress [75, 76], as well as activates
GSK3, which may contribute to apoptosis. Several reports
showed that GSK3 inhibitors reduce toxicity of oxidative
stress [77, 78]. Thus, inhibition of GSK3 may be neuropro-
tective in Alzheimer’s disease in part by reducing oxidative
stress-induced neurotoxicity.
Neurotrophic factor deﬁciency has been linked with
neuronal loss in Alzheimer’s disease. Studies of insulin-
like growth factor-I (IGF-1) are particularly interesting
because IGF-1 deﬁciency has been linked to Alzheimer’s
disease and IGF-1-induced cellular signaling contributes to
maintaining inhibition of GSK3 by activating the PI3K-
Akt pathway. Additionally, GSK3 inhibition has been linked
to increases in IGF-I in the brain [79]. Bol´ os and col-
leagues [79] used megalin, an IGF-I receptor interacting
protein that is associated with transport of IGF-1, and
found that in MDCK cells transiently transfected with or
without mini-megalin, a cDNA encoding the two peri-
membrane extracellular cysteine-rich domains, the trans-
membrane region,and thecytoplasmicregionofthemegalin
gene, treatment with the GSK3 inhibitor NP12 stimulated
internalization of IGF-I and cell-surface megalin expression.
Moreover, treatment of APP/PS1 transgenic mice with
NP12 signiﬁcantly increased both brain and CSF IGF-I
levels. Collectively this data suggests that inhibition of
over-active GSK3β that appears to occur in Alzheimer’s
disease can promote IGF-I expression and counteract Aβ-
induced toxicity. Brain-derived neurotrophic factor (BDNF)
activation of TrkB receptors is also responsible for activation
of the PI3K/Akt pathway and inhibition of GSK3β via Ser9
phosphorylation [80–82]. Decreases in hippocampal and
cortical BDNF levels have been reported in Alzheimer’s
disease [83–85], which could promote an increase in GSK3
activity. Elliottand colleagues[85]showed thatin neuronally
diﬀerentiated P19 mouse embryonic carcinoma cells, BDNF
altered tau phosphorylation, and that inhibition of GSK3
with lithium reduced tau phosphorylation. BDNF has also
been linked to promotion of anti-apoptotic signaling via
the PI3K/Akt pathway. Hetman and colleagues [86]f o u n d
that trophic factor withdrawal promoted inhibition of the
cell survival mediator PI3K and activated the pro-apoptotic
GSK3, which was reversed by PI3K activating treatments,
such as BDNF, by treatment with a GSK3 inhibitor, or
after transient transfection of a kinase-dead GSK3 mutant.
Overexpression of wild-type or mutant β-catenin, in which
all GSK3β-targeted serines were mutated to alanines, had
no eﬀect on GSK3β-mediated neuronal apoptosis [86].
Thus, neurotrophin deﬁciency in Alzheimer’s disease may
contribute to abnormally active GSK3 that can promote
neurotoxicity.
3.6. Mechanisms by Which GSK3 May Impede Cell Survival
from Insults. GSK3 has been reported to promote apoptosis
by regulating the actions of proteins involved in apoptosis
signaling and by regulating transcription factors known to6 International Journal of Alzheimer’s Disease
regulate the expression of apoptosis modulators. For exam-
ple, GSK3 has beenreported to regulate Bax, a pro-apoptotic
Bcl2 family member that is commonly associated with
the release of cytochrome c. Under apoptotic conditions,
Bax undergoes a conformational change associated with its
translocation from the cytosol to the mitochondria where
it facilitates cytochrome c release in apoptotic signaling
[87–89]. GSK3 can directly phosphorylate Bax on Ser-163,
which results in the activation of Bax [90] and inhibition of
GSK3 with lithium prevented Bax activation and subsequent
cytochrome c release [91]. Another Bcl2 family member,
Mcl-1, an anti-apoptotic protein that can be induced after
cellular stress to promote cell survival, is phosphorylated
on Ser159 by GSK3 to promote Mcl1 degradation, thereby
reducing the protective action of Mcl-1 [92, 93]. By these
and other actions on the apoptotic signaling pathway, GSK3
can reduce cellularresilience to stress and promote apoptotic
signaling.
Several transcription factors that are inhibited by GSK3
normally promote mechanisms that promote cellular sur-
vival responses to stresses that are potentially lethal insults
[1]. These include heat shock factor protein 1 (HSF-1),
cyclic AMP response element-binding protein (CREB), and
others, impairments of which are well-documented to
increase the susceptibility of cells to toxic insults. HSF-1, for
example, promotes the expression of heat shock proteins,
chaperones that combat cellular stress. Chu and colleagues
[94] reported that GSK3 reduced HSF-1 activity and
increased susceptibility to environmental stressors. Xavier
and colleagues [95] showed that overexpression of GSK3β
repressed HSF-1 transcriptional activity and DNA-binding.
CREB, which can support cell survival and is activated by
phosphorylation at Ser133, also can be negatively regulated
by GSK3 [1, 96]. Activation of CREB has been reported to
be impaired in Alzheimer’s disease hippocampal tissues [97,
98]. Since GSK3 inhibits CREB activity [1, 96, 99], increased
GSK3 activity may contribute to the Alzheimer’s disease-
induced decrease of phospho-CREB-mediated neuroprotec-
tion. Thus, by regulating these and other transcription fac-
tors that inﬂuence the expression of proteins that modulate
cellular responses to stress [1], GSK3 may contribute to
setting the threshold for apoptotic signaling, which may be
lowered in Alzheimer’s disease.
3.7.GSK3PromotesDecreased CellSurvivalinOtherNeurode-
generative Diseases. Many componentsofneurodegenerative
processes are common among various neurodegenerative
diseases, including apoptosis and mechanisms regulating
apoptosis. Thus, it is not surprising that, similarly with
Alzheimer’s disease, GSK3 has also been linked to neuronal
death in other neurological diseases. For example, prion
disease shares with Alzheimer’s disease accumulations of
protein aggregates and neuronal death [100, 101]. Mouse
embryonic cortical neurons (E17) treated with varying
concentrations of prion protein (PrP) peptide exhibited
increased GSK3 activity and increased tau phosphorylation,
which was prevented by pretreatment with lithium. GSK3β
activation and hyperphosphorylation of tau has also been
identiﬁed in Lafora Disease, an autosomal recessive form
of progressive myoclonus epilepsy that is characterized
by dementia and rapid neurological deterioration [102].
Amyotrophic lateral sclerosis has been linked to mutations
in superoxide dismutase type 1 (SOD1), and expression of
mutantSOD1inmotorneuronsincreased GSK3activityand
apoptosis, and GSK3 inhibitors provided protection from
apoptosis [77]. Thus, there appear to be a variety of disease-
associated conditions that can cause abnormal activation of
GSK3 that contributes to the neurodegenerative process.
4.GSK3ImpedesExtrinsicApoptoticSignaling
In contrast to the many studies of intrinsic apoptotic
signaling mechanisms in association with loss of cell via-
bility in Alzheimer’s disease, few studies have addressed
the possibility that death receptor-mediated extrinsic apop-
totic signaling is involved in Alzheimer’s disease. Plasma
membrane death receptors that can initiate apoptosis are
members of the tumor necrosis factor (TNF) receptor
family that contain conserved intracellular death domains,
which includes Fas (CD95/Apo1), TNF-R1 (p55/CD120a),
TNF-related apoptosis-inducing ligand receptor-1 (TRAIL-
R1/DR4), and TRAIL-R2 (DR5/Apo2/TRICK2/KILLER).
Studies in postmortem Alzheimer’s disease brain and par-
ticularly in Aβ-treated cells in vitro have provided some
evidence for increased death receptor-induced apoptotic
signaling pathway [103–111]. However, the contribution
of death receptor-initiated apoptosis in Alzheimer’s disease
remains to be ﬁrmly established.
Althoughitremains unclear if death receptors contribute
to cell loss in Alzheimer’s disease, we can surmise that
GSK3 is highly unlikely to contribute to this potential
neuropathologicalmechanism. ThisisbecauseGSK3impairs
deathreceptor-induced apoptoticsignaling, asopposedto its
promotion of intrinsic apoptotic signaling [2]. The concept
that GSK3 inhibits death receptor-induced apoptosis fol-
lowed the discovery that GSK3β knockout mice died during
embryonicdevelopmentduetomassive hepatocyteapoptosis
[112], which demonstrated that GSK3β is an important
inhibitor of TNFα-induced apoptosis. This inhibitory eﬀect
of GSK3 on extrinsic apoptotic signaling was extended to all
other death receptors, as reviewed [2]. The mechanism for
this action was found to be due to the presence of GSK3
in a death receptor-associated anti-apoptotic complex that
impedes the initiation of apoptotic signaling [113]. Thus,
several studies have clearly established that GSK3 is anti-
apoptotic in death receptor-mediated signaling.
If death receptor-induced apoptosis does contribute to
cell loss in Alzheimer’s disease, the anti-apoptotic action of
GSK3in thisprocess couldvery likelylimit the application of
inhibitors of GSK3 as therapeutic agents in Alzheimer’s dis-
ease because they would be able to promote extrinsic apop-
totic signaling. This complication was exquisitely demon-
strated in a study of the eﬀects of in vivo treatment with
the GSK3 inhibitor lithium, which demonstrated increased
neuronal apoptosis mediated by lithium’s promotion of Fas-
mediated apoptotic signaling [114] .W h e t h e ro rn o tt h i s
detrimental action of GSK3 inhibitors would be deleteriousInternational Journal of Alzheimer’s Disease 7
in Alzheimer’s disease depends on whether death receptor-
induced apoptotic pathways are activated in Alzheimer’s
disease, a question that remains unresolved.
5.Conclusions
GSK3 has been shown to be associated with the major
neuropathological markers of Alzheimer’s disease and to be
abnormally activated or expressed in Alzheimer’s disease
brains, particularly in association with neuropathological
or degenerative markers. GSK3 is activated by Aβ and
promotes both Aβ production and its neurotoxic actions.
GSK3 phosphorylates tau and may promote oligomeriza-
tion of tau and its aggregation, which can contribute to
neurotoxicity. Apoptosis may contribute to neuronal loss in
Alzheimer’s disease, and GSK3 promotes intrinsic apoptotic
signaling induced by many insults, some of which may be
involved in neurodegeneration in Alzheimer’s disease. GSK3
promotes intrinsic apoptotic signaling both by regulating
signaling proteins involved in apoptosis and regulating
transcription factors that control the expression of proteins
that modulate cellular responses to stress. Altogether, much
evidenceindicates that GSK3is an integral component of the
neurodegenerative processes in Alzheimer’s disease.
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